Abstract
Aicardi-Goutières Syndrome (AGS) is a monogenic leukodystrophy with pediatric onset, clinically characterized by a variable degree of neurologic impairment. It belongs to a group of condition called type I interferonopathies that are characterized by abnormal overproduction of interferon alpha, an inflammatory cytokine which action is mediated by the activation of two of the four human Janus Kinases. Thanks to an ever-increasing knowledge of the molecular basis and pathogenetic mechanisms of the disease, Janus Kinase inhibitors (JAKIs) have been proposed as a treatment option for selected interferonopathies. Here we reported the 24 months follow-up of the fifth AGS patient treated with ruxolitinib described so far in literature. The treatment was globally well tolerated; clinical examinations and radiological images demonstrated a progressively improving course. It is however to note that patients presenting with mild and spontaneously improving course have been reported. Large natural history studies on AGS spectrum are strongly required in order to get a better understanding of the results emerging from ongoing therapeutic trials on such rare disease.
This is a preview of subscription content, log in via an institution to check access.
Data availability
All data generated or analyzed during this study are included in this published article.
Code availability
Not applicable.
References
Adang LA, Gavazzi F, Jawad AF, Cusack SV, Kopin K, Peer K, Besnier C, De Simone M, De Giorgis V, Orcesi S, Fazzi E, Galli J, Shults J, Vanderver A (2020) Development of a neurologic severity scale for Aicardi Goutières Syndrome. Mol Genet Metab 130(2):153–160. https://doi.org/10.1016/j.ymgme.2020.03.008
Adang L, Gavazzi F, De Simone M, Fazzi E, Galli J, Koh J, Kramer-Golinkoff J, De Giorgis V, Orcesi S, Peer K, Ulrick N, Woidill S, Shults J, Vanderver A (2020) Developmental outcomes of Aicardi Goutières syndrome. J Child Neurol 35(1):7–16. https://doi.org/10.1177/0883073819870944
Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 58(Suppl 1):i43–i54. https://doi.org/10.1093/rheumatology/key276
Galli J, Gavazzi F, De Simone M, Giliani S, Garau J, Valente M, Vairo D, Cattalini M, Mortilla M, Andreoli L, Badolato R, Bianchi M, Carabellese N, Cereda C, Ferraro R, Facchetti F, Fredi M, Gualdi G, Lorenzi L, Meini A, Orcesi S, Tincani A, Zanola A, Rice G, Fazzi E, AGS study group (2018) Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis. Medicine (Baltim) 97(52):e13893. https://doi.org/10.1097/MD.0000000000013893
Green EM, Stroud L, Marx C, Cronje J (2020) Child development assessment: Practitioner input in the revision for Griffiths III. Child Care Health Dev 46(6):682–691. https://doi.org/10.1111/cch.12796
Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, Brogan PA, Rice GI, Crow YJ, Dale RC (2018) An open-label trial of JAK 1/2 blockade in progressive. Neurology 90(6):289–291. https://doi.org/10.1212/WNL.0000000000004921
La Piana R, Uggetti C, Roncarolo F, Vanderver A, Olivieri I, Tonduti D, Helman G, Balottin U, Fazzi E, Crow YJ, Livingston J, Orcesi S (2016) Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome. Neurology 86(1):28–35. https://doi.org/10.1212/WNL.0000000000002228
Livingston JH, Crow YJ (2016) Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières syndrome and beyond. Neuropediatrics 47(6):355–360. https://doi.org/10.1055/s-0036-1592307
Melki I, Frémond ML (2020) Type I interferonopathies: from a novel concept to targeted therapeutics. Curr Rheumatol Rep 22(7):32. https://doi.org/10.1007/s11926-020-00909-4
Neven B, Al Adba B, Hully M, Desguerre I, Pressiat C, Boddaert N, Duffy D, Rice GI, Seabra L, Frémond ML, Blanche S, Crow YJ (2020) JAK Inhibition in the Aicardi-Goutières syndrome. N Engl J Med 383(22):2190–2191. https://doi.org/10.1056/NEJMc2031081
Palisano RJ, Hanna SE, Rosenbaum PL, Russell DJ, Walter SD, Wood EP, Raina PS, Galuppi BE (2000) “Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 80(10):974–985
Paulson A, Vargus-Adams J (2017) Overview of four functional classification systems commonly used in cerebral palsy. Children (Basel) 4(4). https://doi.org/10.3390/children4040030
Rice GI, Melki I, Frémond ML, Briggs TA, Rodero MP, Kitabayashi N, Oojageer A, Bader-Meunier B, Belot A, Bodemer C, Quartier P, Crow YJ (2017) Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol 37(2):123–132. https://doi.org/10.1007/s10875-016-0359-1
Tonduti D, Izzo G, D’Arrigo S, Riva D, Moroni I, Zorzi G, Cavallera V, Pichiecchio A, Uggetti C, Veggiotti P, Orcesi S, Chiapparini L, Parazzini C (2019) Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications. Mol Genet Metab 126(4):489–494. https://doi.org/10.1016/j.ymgme.2019.02.006
Tonduti D, Fazzi E, Badolato R, Orcesi S (2020) Novel and emerging treatments for Aicardi-Goutières syndrome. Expert Rev Clin Immunol 16(2):189–198. https://doi.org/10.1080/1744666X.2019.1707663
Tüngler V, König N, Günther C, Engel K, Fiehn C, Smitka M, von der Hagen M, Berner R, Lee-Kirsch MA (2016) Response to: ‘JAK inhibition in STING-associated interferonopathy’ by Crow et al. Ann Rheum Dis 75(12):e76. https://doi.org/10.1136/annrheumdis-2016-210565
Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-Daher MT, Rice GI, Dhir S, Wheeler AP, Dhir A, Albawardi W, Frémond ML, Seabra L, Doig J, Blair N, Martin-Niclos MJ, Della Mina E, Rubio-Roldán A, García-Pérez JL, Sproul D, Rehwinkel J, Hertzog J, Boland-Auge A, Olaso R, Deleuze JF, Baruteau J, Brochard K, Buckley J, Cavallera V, Cereda C, De Waele LMH, Dobbie A, Doummar D, Elmslie F, Koch-Hogrebe M, Kumar R, Lamb K, Livingston JH, Majumdar A, Lorenço CM, Orcesi S, Peudenier S, Rostasy K, Salmon CA, Scott C, Tonduti D, Touati G, Valente M, van der Linden H, Van Esch H, Vermelle M, Webb K, Jackson AP, Reijns MAM, Gilbert N, Crow YJ (2020) cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet 52(12):1364–1372. https://doi.org/10.1038/s41588-020-00737-3
Uggetti C, La Piana R, Orcesi S, Egitto MG, Crow YJ, Fazzi E (2009) Aicardi-Goutieres syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol 30(10):1971–1976. https://doi.org/10.3174/ajnr.A1694
Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, Jaffe N, Yum SW, Collins A, Keller SR, Lebon P, Meritet JF, Rhee J, Takanohashi A, Armangue T, Ulrick N, Sherbini O, Koh J, Peer K, Besnier C, Scher C, Boyle K, Dubbs H, Kramer-Golinkoff J, Pizzino A, Woidill S, Shults J (2020) Janus Kinase Inhibition in the Aicardi-Goutières syndrome. N Engl J Med 383(10):986–989. https://doi.org/10.1056/NEJMc2001362
Author information
Authors and Affiliations
Contributions
EM, SM: study concept and design, neurological data collection and analysis, manuscript preparation; CA: functional scale application, manuscript revision; CP, GI: neuroimaging evaluation, manuscript revision; JG, DS, CC: genetic and interferon signature analysis, manuscript revision; SO, PV, GZ: study concept and design, manuscript revision; DD, FP: general pediatric follow-up and data collection, manuscript preparation; DT: study concept and design, neurological data collection and analysis, manuscript revision. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflicts of interest/Competing interests
The authors have no conflicts of interest to declare that are relevant to the content of this article.
Ethics approval
All procedures were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Consent to participate
Informed consent was obtained from the parents of the patient described in this study.
Consent for publication
Not applicable. Information is anonymized and the submission does not include images that may identify the person.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mura, E., Masnada, S., Antonello, C. et al. Ruxolitinib in Aicardi-Goutières syndrome. Metab Brain Dis 36, 859–863 (2021). https://doi.org/10.1007/s11011-021-00716-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-021-00716-5